The global sepsis diagnostics market is projected to expand at a CAGR of around 8% from 2021 to 2031. The market is mainly driven by surging demand for assays & reagents across geographies.

Sepsis diagnostics has acquired increased attention over the years, given the alarmingly increasing rates of sepsis episodes amongst patients of all age groups across hospital settings. The market is witnessing a slew of new diagnostic approaches, mostly based on automated detection technologies, given the high demand for precision and time-based diagnostic solutions.

Request Sample  https://www.factmr.com/connectus/sample?flag=S&rep_id=391     

Key Segments Covered in the Sepsis Diagnostics Industry Report

• Sepsis Diagnostics by Product :

  • Blood Culture Media Sepsis Diagnostics
  • Sepsis Diagnostics Instruments
  • Sepsis Diagnostics Assays & Reagents

• Sepsis Diagnostics by Method :

  • Conventional Sepsis Diagnostics
  • Automated Sepsis Diagnostics

• Sepsis Diagnostics by Pathogen :

  • Gram-Negative Bacterial Sepsis Diagnostics
  • Gram-Positive Bacterial Sepsis Diagnostics
  • Fungal Sepsis Diagnostics
  • Other Pathogens-based Sepsis Diagnostics

• Sepsis Diagnostics by Technology :

  • Microbiology-based Sepsis Diagnostics
  • Molecular Sepsis Diagnostics
  • Immunoassays-based Sepsis Diagnostics
  • Other Technology-based Sepsis Diagnostics

• Sepsis Diagnostics by Region :

  • North America Sepsis Diagnostics Market
  • Latin America Sepsis Diagnostics Market
  • Europe Sepsis Diagnostics Market
  • APEJ Sepsis Diagnostics Market
  • Japan Sepsis Diagnostics Market
  • Middle East & Africa Sepsis Diagnostics Market

Competitive Landscape

The global market for sepsis diagnostics is highly fragmented. The prominent companies rely on a variety of development tactics, such as broadening product portfolios, strategic mergers and acquisitions, expanding production capabilities, investing in R&D projects, and merging technical improvements into current equipment.

• Becton Dickinson and Company (BD) announced the BACTECTM Platelet Quality Control Media in 2019, earning US FDA certification to identify tainted platelet units in microbiology laboratories, blood banks, and transfusion programmes. Through a culture-based technique, the technology enables doctors to identify possibly tainted platelet donations and help lower the risk of sepsis.
• Similarly, in 2018, Thermo Fisher Scientific released the B.R.A.H.M.S PCT direct point-of-care assay blood test, which enables for the rapid identification of bacterial infection and sepsis. The test is intended to provide procalcitonin (PCT) measurement to acute care settings in order to assist quick management and exact findings for therapeutic solutions.
• T2 Biosystems Inc. has got clearance for its T2SARS-CoV-2TM Panel, a molecular diagnostic test that identifies SARS-P1 CoV-2’s variant, which was recently verified in the United States. This panel has a clinical sensitivity of 95% and a specificity rate of 100%, and it produces findings in less than two hours when performed on a fully automated T2Dx® device. As the COVID-19 virus causes sepsis and mortality, these panels remain therapeutically important.

Key Challenges Prevalent in the Global Sepsis Diagnostics Market

Expensive Diagnostic Tests may Impede Growth Prospects

A molecular diagnostic test may cost between USD 300 and USD 3,000, which is significantly more expensive than blood culture tests, which can cost as low as USD 28–35, according to the National Institutes of Health.

Although companies focused on creating computer – aided diagnostic instruments for recognizing sepsis based on sophisticated technologies such as sepsis molecular diagnostics, public hospitals and scholarly research laboratories cannot afford such systems due to funding constraints. It is also becoming a key impediment to the expansion of the market for sepsis diagnosis equipment.